Yonsei University

The Catholic University of Korea Industry-Academic Cooperation Foundation

Byung Ha Chung

Eun Kyung Kim

Sung-Hee Lee

Mi-La Cho

Seon-Yeong Lee

Sung-Hwan Park

Eun-Jung Lee

Kyo Chul Koo

Kwang Suk Lee

Seok-Jung Kim

Min Jung Park

Chul Woo Yang

Kyoung-Woon Kim

Eun Ji Yang

Jeong-hee Jeong

Su-Jin Moon

The present disclosure relates to a method and apparatus for diagnosing urinary disturbances by simultaneously measuring a urinary flow rate and residual urine. The method for diagnosing urinary disturbances according to the present disclosure includes obtaining at least one ultrasonic image of a bladder for each unit time from a patient who is urinating, obtaining at least one urine region image for each unit time from the at least one ultrasonic image for each unit time, calculating at least one estimated urine volume for each unit time based on an area of the at least one urine region image for each unit time, calculating at least one parameter value with respect to urinary disturbances based on the at least one estimated urine volume for each unit time, and outputting the at least one parameter value.

Method and apparatus for diagnosing urinary disturbances by simultaneously measuring urinary flow rate and residual urine

The present invention relates to a mesenchymal stem cell having immunomodulatory activity and a preparation method therefor and, more specifically, to: a rapamycin-treated mesenchymal stem cell having immunomodulatory activity, which expresses any one or more cell surface factors selected from the group consisting of CCR1, CCR2, CCR3, CCR4, CCR7, CCR9 and CXCR4; a cell therapy composition comprising the mesenchymal stem cell, for preventing or treating immune disorders; and a preparation method for the mesenchymal stem cell having immunomodulatory activity. The rapamycin-treated mesenchymal stem cell having immunomodulatory activity, according to the present invention, has increased expression of IDO, TGF-&#x3b2; and IL-10 which are factors having immunomodulatory activity, has decreased expression of Phospho-mTOR, Rictor and Ractor which are signal transduction factors of mTOR, and has increased expression, in the cell, of autophagic inducer Beclin1, ATG5, ATG7, LC3I or LCII. If this cell is used as a cell therapy in individuals having immune disorders, it is possible to effectively treat immune disorders.

MTOR/STAT3 signal inhibitor-treated mesenchymal stem cell having immunomodulatory activity, and cell therapy composition comprising same, for preventing or treating immune disorders

Growing community of inventors

Seoul, South Korea

Byung Ha Chung